

1 **Comparison of control and transmission of COVID-19 across epidemic waves in**

2 **Hong Kong: an observational study**

3 Bingyi Yang<sup>1</sup>, Yun Lin<sup>1</sup>, Weijia Xiong<sup>1</sup>, Chang Liu<sup>1</sup>, Huizhi Gao<sup>1</sup>, Faith Ho<sup>1</sup>, Jiayi Zhou<sup>1</sup>, Ru

4 Zhang<sup>1</sup>, Jessica Y. Wong<sup>1</sup>, Justin K. Cheung<sup>1</sup>, Eric H. Y. Lau<sup>1,2</sup>, Tim K. Tsang<sup>1</sup>, Jingyi Xiao<sup>1</sup>,

5 Irene O. L. Wong<sup>1</sup>, Mario Martín-Sánchez<sup>1</sup>, Gabriel M. Leung<sup>1,2</sup>, Benjamin J. Cowling<sup>1,2</sup>,

6 Peng Wu<sup>1,2</sup>

7

8 **Affiliations:**

9 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of  
10 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong  
11 Special Administrative Region, China.

12 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology  
13 Park, New Territories, Hong Kong.

14

15 **Corresponding author:**

16 Ben Cowling: School of Public Health, Li Ka Shing Faculty of Medicine, The University of  
17 Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong

18 Email: [bcowling@hku.hk](mailto:bcowling@hku.hk)

19 Tel: +852-3917 6711

20

21 **Running head:** Burden of COVID-19 and pandemic responses

22 **Keywords:** COVID-19, control, pandemic response, interventions, impact, disease

23 burden

24 **Word count:** 269 (Abstract)

25 3,859 (Main text)

26 **ABSTRACT**

27 **Background:** Hong Kong contained COVID-19 for two years, but experienced a large  
28 epidemic of Omicron BA.2 in early 2022 and endemic transmission of Omicron  
29 subvariants thereafter.

30 **Methods:** We examined the use and impact of pandemic controls in Hong Kong by  
31 analysing data on more than 1.7 million confirmed COVID-19 cases and characterizing  
32 non-pharmaceutical and pharmaceutical interventions implemented from January 2020  
33 through to 30 December 2022. We estimated the daily effective reproductive number  
34 ( $R_t$ ) to track changes in transmissibility and effectiveness of community-based  
35 measures against infection over time. We examined the temporal changes of  
36 pharmaceutical interventions, mortality rate and case-fatality risks (CFRs), particularly  
37 among older adults.

38 **Findings:** Hong Kong experienced four local epidemic waves predominated by the  
39 ancestral strain in 2020 and early 2021 and prevented multiple SARS-CoV-2 variants  
40 from spreading in the community before 2022. Strict travel-related, case-based, and  
41 community-based measures were increasingly tightened in Hong Kong over the first  
42 two years of the pandemic. However, even very stringent measures were unable to  
43 contain the spread of Omicron BA.2 in Hong Kong. Despite high overall vaccination  
44 uptake (>70% with at least two doses), high mortality was observed during the  
45 Omicron BA.2 wave due to lower vaccine coverage (42%) among adults  $\geq 65$  years of  
46 age. Increases in antiviral usage and vaccination uptake over time through 2022 was  
47 associated with decreased case fatality risks.

48 **Interpretation:** Integrated strict measures were able to reduce importation risks and  
49 interrupt local transmission to contain COVID-19 transmission and disease burden  
50 while awaiting vaccine development and rollout. Increasing coverage of pharmaceutical

51 interventions among high-risk groups reduced infection-related mortality and mitigated  
52 the adverse health impact of the pandemic.

53 **Funding:** Health and Medical Research Fund

54

55 **Key words:** COVID-19; SARS-CoV-2; pandemic preparedness; pandemic responses;

56 public health

57

## 58 INTRODUCTION

59 The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 led to  
60 billions of infections, and more than 17 million deaths had been recorded globally from  
61 late 2019.<sup>1</sup> Compared to the most recent influenza pandemic in 2009-2011, significant  
62 improvements have been made in pandemic responses including surveillance,  
63 diagnostics, and innovation and rapid development of vaccines and antivirals.<sup>2</sup> Once  
64 effective pharmaceuticals became available for SARS-CoV-2, many locations began to  
65 transition away from the use of stringent non-pharmaceutical interventions (NPIs) to  
66 control transmission, given the substantial social and economic costs of sustaining these  
67 measures. Rapid evolution of SARS-CoV-2 resulted in the emergence of new variants,  
68 including Omicron that has dominated the largest waves of global transmission.<sup>3,4</sup> The  
69 timing and impact of pandemic waves have varied substantially around the world.<sup>5-7</sup>  
70 Identifying the optimal combination of pharmaceutical and non-pharmaceutical  
71 measures at different points in time remains a priority not only for reflecting on the  
72 response to the COVID-19 pandemic but also for preparing for the next global outbreak.

73  
74 As a unique case, Hong Kong adopted a stringent containment strategy since 2020, with  
75 successful control of four local epidemic waves in 2020 and the first half of 2021, and no  
76 major outbreaks between April and December 2021. However, a large community  
77 epidemic of Omicron beginning in January 2022 caused a large number of fatalities  
78 within three months, despite the availability of COVID-19 vaccines for over a year by  
79 that time, and more stringent NPIs being implemented to attempt to contain  
80 transmission.<sup>3,8</sup> Here, we systematically examine the progression and control of COVID-  
81 19 pandemic waves in Hong Kong, focusing on locally adopted control measures and

82 their impact on transmission and burden of COVID-19, to identify critical factors in  
83 response and preparedness over the course of the pandemic.

84

## 85 **METHODS**

### 86 ***Sources of data***

87 We obtained demographic, clinical, and epidemiological data (situation as of 29 January  
88 2023) on all laboratory-confirmed and self-reported cases between January 2020 and  
89 December 2022 from the Hong Kong Department of Health and Hospital Authority of  
90 Hong Kong. Cases, regardless of symptoms, were recorded as laboratory-confirmed  
91 when positive by reverse transcription polymerase chain reaction (RT-PCR) tests  
92 throughout the pandemic and recorded as confirmed based on self-reported positive  
93 rapid antigen tests (RAT) since 26 February 2022. Confirmed COVID-19 cases were  
94 classified into mild/moderate, serious, critical, and fatal according to clinical outcomes,  
95 while confirmed cases with available epidemiological information were further  
96 classified into imported, linked-to-imported, local, and contacts of local cases  
97 (Appendix).

98

99 We classified the COVID-19 pandemic in Hong Kong into six waves by confirmation date  
100 of cases. Each wave was divided into pre-peak (16-50 days before peak), peak (15 days  
101 before or after peak), and post-peak periods (16-50 days after peak) to reflect the  
102 trajectory, where peak was defined as the day recording the largest number of  
103 confirmed cases. Waves 5 and 6 were further divided into two periods to reflect  
104 changes in healthcare and predominant virus variant over the epidemic, namely 5a (31  
105 Dec 2021 - 6 Feb 2022), 5b (7 Feb - 22 May 2022), 6a (23 May - 30 Sep 2022) and 6b (1  
106 Oct - 31 Dec 2022). Although the Hong Kong SAR Government classified the resurgence

107 of infections in June 2022 with Omicron BA.4/5 as a continuation of the fifth wave,  
108 because daily cases never declined to zero prior to the resurgence, here we refer to this  
109 as the sixth wave for clarity and consistency. Our project was approved by the  
110 Institutional Review Board of the University of Hong Kong/Hospital Authority Hong  
111 Kong West Cluster.

112

### 113 ***Characterization of non-pharmaceutical interventions***

114 Information on NPIs implemented in Hong Kong was collected through the government  
115 press releases and classified into travel-related, community-wide, and case-based  
116 measures (details in Appendix). Travel-related measures include entrance restrictions,  
117 inbound traveller testing, quarantine, and exemptions. Community-wide measures  
118 include school closures, work-from-home policies, mask wearing, restrictions on group  
119 gatherings and measures to reduce crowding and mixing in the population. Case-based  
120 interventions refer to targeted measures related to case identification, timely isolation,  
121 and tracing and quarantine of contacts.

122

123 We used contact tracing data to assess the temporal changes in local case clustering  
124 patterns. A cluster was defined as at least two RT-PCR confirmed cases with contact  
125 history and initiated by index local cases (Appendix).<sup>9</sup> We characterized the monthly  
126 distribution and density distribution of cluster size, stratified by waves.

127

### 128 ***Case finding and contact tracing***

129 We obtained data on COVID-19 RT-PCR tests performed in Hong Kong through various  
130 testing schemes (Appendix) up to wave 5a (7 February 2022),<sup>10</sup> including daily  
131 numbers of specimens tested and test positives. The testing schemes focused on

132 different risk populations, including inbound travellers, cases and their close contacts,  
133 patients in clinical settings, and persons in the general community. We describe  
134 temporal changes in testing capacity and case detection proportions and compare the  
135 two-week moving average of numbers of specimens collected from close contacts to  
136 that from the confirmed cases. We report the distribution of the delays between illness  
137 onset and case confirmation for symptomatic cases as indicators of the potential impact  
138 on transmissibility of case finding and isolation across waves, stratified by type of case,  
139 wave and trajectory.

140

#### 141 ***Population behavioural responses to community-based measures***

142 To assess population behavioural responses during the COVID-19 pandemic, we  
143 conducted 107 rounds of cross-sectional random digit dialling telephone surveys from  
144 January 2020 to December 2022 (details in appendix).<sup>11,12</sup> Participants reported on face  
145 mask usage, personal hygiene, and social distancing behaviours in the week prior to  
146 each survey. We calculated the rim-weighted<sup>11</sup> proportion of respondents who reported  
147 specific behaviours in each survey, with binomial confidence intervals (CIs).

148

149 We compared community mobility to the pre-pandemic level (1 January 2020) using  
150 transaction data on Octopus cards, which is an ubiquitous stored-value and age-  
151 stratified payment method for daily public transport.<sup>13</sup> Overall mobility based on all  
152 card types was calculated and weighted by population age-structure. Changes in  
153 community mobility were analysed, stratified by time to the peak of each epidemic  
154 wave and age group. We also obtained data from the Immigration Department of Hong  
155 Kong to assess changes in inbound travellers during the study period.

156

157 ***COVID-19 transmission and impact of non-pharmaceutical interventions***

158 We extended the approach described by Cori *et al.*<sup>14</sup> to estimate the time-varying  
159 effective reproductive number ( $R_t$ ) for imported and local cases separately to  
160 characterise the transmissibility of COVID-19 (Appendix).<sup>15</sup> We inferred the epidemic  
161 curve by infection date for  $R_t$  estimation by applying a deconvolution approach<sup>16</sup> to  
162 incubation period (mean 5.2 (SD 3.9) days for waves 1-4 and mean 3.5 (SD 2.6) days for  
163 waves 5-6)<sup>17,18</sup>, infectiousness relative to onset time<sup>19</sup> and infection-to-report delay  
164 from empirical data.<sup>12</sup>

165

166 We examined the impact of combined NPIs (“NPI package”) on reducing community  
167 transmission by monitoring changes in  $R_t$  for local cases. The inclusion of individual  
168 NPIs was informed by the clustering and the variance explained (Appendix). Log-linear  
169 regression models were used with daily  $R_t$  as an outcome and interventions as time-  
170 varying covariates across waves 1 to 5a, allowing for different initial  $R_t$  and effect of  
171 work-from-home of each wave. We repeated the above analyses by dropping one wave  
172 at each time to test potential changes in NPIs effects across waves.  $R_t$  was estimated for  
173 defined NPI packages representing different intensities of interventions and the initial  
174 condition as reflected by  $R_t$ , i.e., the initial transmissibility in each wave, in comparison  
175 with the scenarios of no NPIs and applying all available NPIs. 95% CIs were estimated  
176 using 1,000 bootstraps of coefficient estimates following a multivariate normal  
177 distribution.

178

179 ***COVID-19 fatality and pharmaceutical interventions***

180 To characterize the changes in disease burden and severity over wave and trajectory,  
181 we used the weekly mortality rate and case-fatality risk (CFR) for the overall population,



182 older adults  $\geq 65$  years, and unvaccinated individuals, respectively. Within each group  
183 and study period, the weekly mortality rate was calculated as the weekly number of  
184 COVID-19 deaths over person-times observed, while the CFR was defined as the number  
185 of deaths over the total number of confirmed COVID-19 cases (details in appendix). Data  
186 from 1 October 2022 onwards were excluded due to potentially reduced ascertainment  
187 of COVID-19 cases after that date.

188

189 Two vaccines including the inactivated vaccine CoronaVac (Sinovac) and the mRNA  
190 vaccine BNT162b2 (BioNTech/Fosun Pharma/Pfizer) were provided for free in Hong  
191 Kong starting from February 2021, with third doses available for adults since November  
192 2021. We collected age-specific population and daily numbers of vaccine doses  
193 administered by age from the territory-wide vaccine registry to calculate the proportion  
194 fully vaccinated ( $\geq 2$  doses) among the overall population and older adults  $\geq 65$  years of  
195 age, stratified by wave and trajectory.

196

197 Two COVID-specific oral antiviral drugs, molnupiravir (Merck) and  
198 nirmatrelvir/ritonavir (Pfizer) have been authorized for use in Hong Kong since late  
199 February 2022 and mid-March 2022 respectively. Drug prescriptions for individual  
200 patients were used to calculate the proportion of patients who were confirmed by  
201 either RT-PCR or RAT and received the antivirals in all ages and unvaccinated older  
202 adults  $\geq 65$  years, stratified by wave and trajectory.

203

204 All analyses were conducted in R version 4.0.0 (R Foundation for Statistical Computing,  
205 Vienna, Austria).

206

## 207 RESULTS

### 208 *Non-pharmaceutical interventions and COVID-19 transmission*

209 Hong Kong experienced six epidemic waves from January 2020 through December 2022  
210 (Figure 1, Figure S1 and Table S1), with over 2.6 million laboratory- and RAT-  
211 confirmed COVID-19 cases (Table 1). Notwithstanding differential ascertainment by  
212 wave, only 12,631 (0.5%) cases were confirmed during the first four epidemic waves  
213 predominated by the SARS-CoV-2 ancestral strain, corresponding to 1.6 cases per 1,000  
214 population. In the second half of 2021, in total there were 841 (98%) imported cases  
215 but only five sporadic/index local cases reported (Table 1, S2). A superspreading event  
216 associated with a case of Omicron BA.2.2 who acquired the infection in a quarantine  
217 hotel initiated a large fifth wave, with a cumulative incidence of 162 cases per 1,000  
218 persons during January-May 2022 (wave 5), and the incidence rates dropped by 90%  
219 afterwards (Figure 1).

220

221 The estimated  $R_t$  for local infections over the epidemic waves (Figure 1B) indicated that  
222 transmissibility of SARS-CoV-2 decreased following (re-)implementation of strict NPIs  
223 and rose after relaxation of the measures during the first four waves. In the Omicron  
224 BA.2.2 wave (wave 5),  $R_t$  remained above 1 even after increasingly stringent control  
225 measures were implemented during pre-peak and peak periods (wave 5), and mostly  
226 fluctuated at around 1 during the Omicron BA.4/5 wave (wave 6).

227

228 Hong Kong adopted stringent border controls to prevent importation of cases, including  
229 suspending 12 out of 15 boundary control points, barring entry of non-local residents if  
230 they have been to overseas places, and mandating on-arrival quarantine with RT-PCR  
231 testing in designated facilities for up to 21 days (Figure 1C-D and Table S3-4). We

232 observed a significant decrease in daily passenger arrivals from over 150,000 in January  
233 to below 3,000 since April 2020 (a 98% decrease from January 2020) and an increase in  
234 daily COVID-19 testing for inbound travellers from 1,000 in March 2020 to 6,000  
235 between July and November 2021 (Figures S2-3). As a result, the  $R_t$  for imported cases  
236 was maintained well below 1 since mid-February 2020 (Figure S4) and eventually  
237 became unquantifiable due to too few sporadic transmission events during the  
238 following waves (Table 1).

239

240 Hong Kong implemented proactive case finding and contact tracing measures, with  
241 substantially expanded laboratory testing capacity over time, leading to gradually  
242 shortened onset-to-report intervals (e.g., for close contacts of local cases from a median  
243 of 5 to 3 days between wave 3 and 5a) (Figures S5-7, Table S5). Quarantine of close  
244 contacts were enforced in designated quarantine facilities since January 2020 and home  
245 quarantine was introduced since February 28, 2022, and continued until December 28,  
246 2022. Numbers of specimens collected from close contacts for testing peaked before the  
247 fifth wave, but the ratio to confirmed case numbers decreased substantially compared  
248 to previous waves (Figure S5), consistent with widespread community transmission. In  
249 clinical settings, testing was required for all pneumonia inpatients and outpatients with  
250 respiratory illness since February 2020, and expanded to all hospital admissions in May  
251 2020 (Figure 1 and S5). In the community, predefined higher-risk individuals were  
252 required to receive regular testing since May 2020, with an increasing contribution to  
253 the tested specimens from 40% in the third wave to 88% in wave 5a.

254

255 The government closed all schools and recommended civil servants to work remotely in  
256 late January 2020 (Figure 1A and Table S2-4). The work-from-home recommendation

257 was removed and re-introduced in subsequent waves, while schools re-opened with  
258 restrictions when local cases were low (Figure 1). During the second wave, the  
259 government instituted infection control requirements for group gatherings, restaurant  
260 capacity and operating hours and other non-essential business sectors in response to  
261 local case clusters associated with restaurants and bars. These measures were relaxed  
262 and retightened through the following waves. A face mask mandate in all indoor and  
263 outdoor public areas was issued since the third wave in mid-July 2020 and remained in  
264 place throughout the remaining study period and was only ultimately relaxed in March  
265 2023.

266

267 Telephone surveys conducted from late January 2020 and December 2022 (total  
268 n=82,562) revealed notable behavioural changes in population response to the  
269 implemented NPIs. Physical distancing behaviours were observed at high proportions  
270 during waves 1-6 especially when local transmission was high (67% to 90%; Figure S8).  
271 Face mask use increased to a high level in January 2020 and remained very high (over  
272 98%) throughout the study period. Reduced behaviour changes and risk perceptions  
273 were observed during the period between wave 4 and 5, and during wave 6 (Figures S8-  
274 9). There were notable reductions in public transport transactions, with the greatest  
275 reductions in wave 5 (largest reduction at 37%, 95% CI, 33% to 40%), compared to  
276 previous waves (Figure S10-11). Clusters with more than 10 cases involved were less  
277 frequently observed after strict community-based measurements were implemented in  
278 the third wave, with a median size of 10 (IQR: 5 to 19) (Figure S12).

279

280 We included a combination of NPIs that parsimoniously reflected changes in controlling  
281 local transmission in the multivariate analysis (Appendix, Figure S13; adjusted R<sup>2</sup> 67%),

282 to estimate the effects of different NPI packages. The NPI packages adopted in wave 4  
283 appeared to be the strictest among all the waves (Figure 2A). The initial  $R_t$  for waves  
284 1&2, 3, 4 and 5a were estimated to be 1.2 (95% CI: 1.0 to 1.5), 2.6 (95% CI: 1.9 to 3.5),  
285 3.0 (95% CI: 2.3 to 3.9) and 9.3 (95% CI: 6.5 to 13.4), respectively (Figure 3B and Table  
286 S6). Applying all locally implemented NPIs at the most intensive level was estimated to  
287 bring  $R_t$  down to below 1 (e.g., 0.6, 95% CI: 0.4 to 0.9 for wave 3), except for wave 5a  
288 (3.1, 95% CI: 1.5 to 5.9), while the analysis on the strictest wave-specific NPI packages  
289 showed that only the NPI package used in wave 4 seemed sufficient to control  
290 epidemics in waves 1-3, but was only marginally effective during wave 4. However,  
291 none of the NPI packages from earlier waves could have sufficiently suppressed  
292 Omicron transmission in wave 5 (Figure 2C).

293

#### 294 ***Pharmaceutical interventions against COVID-19***

295 In total 13,134 COVID-19 deaths were reported throughout the six waves, among which  
296 74% (n=9,676) were reported between January and May 2023 (wave 5) with a peak in  
297 the overall mortality rate of 2.36 (95% CI, 2.31 to 2.41) deaths per 10,000 person-  
298 weeks (Figure 3-4). Among all fatal cases recorded, 92% (n=12,073) were amongst  
299 older adults  $\geq 65$  years of age.

300

301 Uptake of the two COVID-19 vaccines in Hong Kong gradually increased during the first  
302 six months after having become available, reaching a plateau between October 2021  
303 and January 2022 (Figure 3). Before wave 5, approximately 70% of the population and  
304 42% of older adults  $\geq 65$  years received  $\geq 2$  doses, but fewer than 10% of the whole  
305 population and fewer than one-tenth of older adults had received a third dose (Figures

306 3-4). The coverage of  $\geq 2$  doses of vaccine increased to 82% among adults  $\geq 65$  years by  
307 the end of wave 6.

308

309 The two antivirals molnupiravir and nirmatrelvir/ritonavir first became available only  
310 during the peak of wave 5 and were provided to 18% of the adult patients  $\geq 65$ y within  
311 one month (Figures 3-4). The usage of antivirals increased to about 40% among adults  
312  $\geq 65$ y.

313

314 The CFR in infected adults  $\geq 65$  years decreased across epidemic waves from 13% (95%  
315 CI, 11% to 16%) in wave 3 to 0.83% (95% CI, 0.76% to 0.89%) in wave 6 (Figure 4B).  
316 Following availability of the antivirals, CFRs among unvaccinated adults  $\geq 65$ y decreased  
317 from 9.4% (95% CI, 7.5% to 11.6%) pre-peak of wave 5 to 3.0% (95% CI, 2.4% to 3.8%)  
318 during the peak of wave 6 (Figure 4E). We observed reduced differences in CFRs and  
319 weekly mortality rate between all and vaccinated adults  $\geq 65$  years along with the  
320 increasing vaccine uptake in this age group (Figure 4F-G).

321

## 322 **DISCUSSION**

323 Using detailed individual case data and territory-wide population data collected during  
324 the COVID-19 pandemic in Hong Kong, we were able to systematically examine the  
325 progression of epidemics from 2020-2022 in relation to local pandemic responses,  
326 including implementation of both NPIs and pharmaceutical interventions over the  
327 course of the pandemic.

328

329 Stringent NPIs aiming to minimize importation risks and interrupt local transmission  
330 chains had been implemented in Hong Kong from early in the pandemic, and

331 successfully controlled multiple epidemic waves in the community caused by the  
332 ancestral strain. These measures reduced COVID-19 mortality in a highly susceptible  
333 population in the absence of effective pharmaceutical interventions through effectively  
334 suppressing the spread of infection.<sup>20</sup> Nevertheless, the containment strategy relying  
335 solely on NPIs may not be sustainable because of the cost and disruption of these  
336 measures. Successful suppression of transmission leaves a large population susceptible  
337 to infection with newly emerging, immunologically distinct viral strains, and the NPIs  
338 would be less effective in preventing pre-symptomatic and superspreading  
339 transmissions, and in controlling infections with a relatively higher transmissibility.<sup>19,21</sup>  
340 In some countries, relaxation of NPIs resulted in increased COVID-19 mortality.<sup>1,22</sup>  
341 Achieving high vaccination coverage in the most vulnerable groups, particularly older  
342 adults, would minimize COVID-19 mortality after containment measures fail or are  
343 relaxed.<sup>23</sup>  
344  
345 Strict travel measures were able to minimize COVID-19 introductions into the  
346 community.<sup>24,25</sup> Despite over 2,000 infections in arriving travellers, only three  
347 independent introductions accounted for 90% of the local cases between the second  
348 and fourth waves.<sup>26</sup> The other cornerstone of the approaches to COVID-19 elimination  
349 in Hong Kong was the strict isolation of all confirmed cases until viral shedding of the  
350 patients reached low levels before discharge, and quarantine of close contacts identified  
351 from contact tracing at designated facilities. While isolation and quarantine likely  
352 reduced transmission of COVID-19, it is well recognized that many infections in the  
353 community were never confirmed, and a number of community epidemics occurred  
354 despite intense contact tracing and timely quarantine.<sup>12</sup> As a consequence, the  
355 containment of COVID-19 in Hong Kong cannot be attributed to strict isolation and

356 quarantine alone, while it is clear that moderate social distancing measures were  
357 necessary to contain community epidemics with the ancestral strain.

358

359 Community-based physical distancing measures were widely adopted in different parts  
360 of the world early in the pandemic,<sup>5</sup> and individual behaviours might have also changed  
361 in response to perceived risk.<sup>27</sup> Our analysis showed that the implementation of  
362 packages of physical distancing measures, including school closure, working from home  
363 and suspension of large gatherings, etc., correlated with subsequent decline in the  
364 effective reproductive number (Figure 2) during epidemics of the ancestral strain but  
365 these declines were not sufficient to achieve containment of the more transmissible  
366 Omicron subvariants. It was not possible to estimate the impact from individual  
367 measures which were often implemented together.

368

369 Containment of COVID-19 in Hong Kong allowed vaccination rollout in early 2021 which  
370 could provide an opportunity for a transition/exit strategy from the use of NPIs for  
371 containment. Despite over 70% of the Hong Kong population being fully vaccinated by  
372 the end of 2021, the vaccine uptake among adults  $\geq 65$  years was low particularly in  
373 adults  $\geq 80$  years (approximately 25%) before the Omicron wave. With a high incidence  
374 of infections with Omicron, there was a high mortality rate of 1,500 per 1,000,000  
375 persons in 2022, the majority of deaths occurring in unvaccinated older adults.

376 Conversely, locations such as Singapore that only considered containment as a  
377 temporary approach prior to reaching high vaccination coverage among vulnerable  
378 groups recorded much lower mortality rates in their Omicron waves.<sup>5,7</sup> If all adults  $\geq 65$ y  
379 were fully vaccinated, a large fraction of deaths in that age group during wave 5 in Hong  
380 Kong might have been prevented. The successful control of community transmission for



381 two years in Hong Kong, and the intention to continue with a containment approach  
382 regardless of vaccination uptake,<sup>28</sup> might have contributed to a lack of urgency in  
383 increasing vaccination uptake among vulnerable groups,<sup>11,29</sup> further exacerbating the  
384 low coverage of vaccine in Hong Kong. Risk communication that address the risk  
385 perception and urgency of vaccine uptake, along with convenient outreach vaccination  
386 programs, could help to improve vaccine uptake in most vulnerable populations.<sup>11</sup>

387

388 Planning for “living with the virus” is a challenge for many different locations with  
389 different control strategies during the pandemic. Clear objectives in responses are  
390 essential for selecting appropriate strategies over the course of the pandemic, and the  
391 ultimate goal is always to minimize severe cases and fatalities, and to protect healthcare  
392 systems from being overwhelmed. In late 2021, emerging variants such as Delta  
393 showing increased immune evasion caused concerns about reduced vaccine-induced  
394 protection against infection.<sup>30</sup> However, evidence suggested that COVID-19 vaccines  
395 had remained highly effective in preventing severe and fatal outcomes from infections  
396 with the variants,<sup>8,31</sup> suggesting that vaccination would still likely be an effective way to  
397 reduce the severe disease burden even if not preventing infections especially in a  
398 population with passive immunity conferred by vaccines.<sup>32-34</sup> While Omicron was  
399 associated with milder disease and lower impact in some locations,<sup>4</sup> infections may  
400 have a similar intrinsic severity to the ancestral virus in persons who have not been  
401 vaccinated or previously infected.<sup>35</sup> Real-time risk assessment of emerging variants  
402 remains a challenge.

403

404 There are several limitations of our study. First, the investigation of health impact of  
405 pandemic control measures did not take into consideration the possible negative effects

406 on economy and quality of life, and the estimates might vary based on local  
407 infrastructure and cultural factors. Second, we estimated the initial transmissibility for  
408 each epidemic wave, but could not attribute the estimates to viral features or  
409 population immunity. However, the increased transmissibility in the fifth wave was  
410 likely due to increased transmissibility and immune invasion of Omicron variant, due to  
411 the low seroprevalence and vaccination acquired antibodies in previous waves.<sup>32-34</sup>

412

413 Experience from Hong Kong has indicated that optimal pandemic control lies in timely  
414 and efficient implementation of NPIs, along with a high level of population adherence  
415 before pharmaceutical interventions become available. Once vaccines or antivirals can  
416 be rolled out, the rationale for continuing to apply disruptive NPIs will gradually  
417 weaken. Our findings highlight the value of continuously assessing the level of  
418 population immunity against severe disease in the light of viral evolution and the  
419 changing availability of pharmaceutical agents. In future pandemics caused by other  
420 novel respiratory pathogens, employing NPIs as an initial and temporary strategy can  
421 help to contain the spread, providing time to implement more sustainable control  
422 measures for high-risk individuals to minimize population mortality and impact on  
423 public health.

424 **ACKNOWLEDGMENTS**

425 We thank the Department of Health and the Health Bureau (former Food and Health  
426 Bureau) of the Hong Kong SAR Government for providing the data for the analysis, and  
427 thank Julie Au and Chloe Chui for technical assistance.

428

429 **FUNDING**

430 This project was supported by the Health and Medical Research Fund from the Health  
431 Bureau of the Hong Kong SAR Government (grant numbers COVID190118 and  
432 21200212), and the Collaborative Research Scheme (Project No. C7123-20G), the  
433 Theme-based Research Scheme (Project No. T11-705/21-N) and the General Research  
434 Fund (Project No. 17110221) from the Research Grants Council of the Hong Kong SAR  
435 Government. The telephone surveys were supported by the Health and Medical  
436 Research Fund (ref: COVID19F04, COVID19F11) from the Health Bureau of the Hong  
437 Kong SAR Government. The funding bodies had no role in the design of the study or in  
438 the analysis and interpretation of data.

439

440 **AUTHOR CONTRIBUTIONS**

441 All authors meet the ICMJE criteria for authorship. The study was conceived by BY, GML,  
442 BJC and PW. Data analyses were conducted by BY, YL, CL, HG, FH, JZ, RZ, WX and TKT.  
443 BY and PW wrote the first draft of the manuscript, and all authors provided critical  
444 review and revision of the text and approved the final version.

445

446 **COMPETING INTERESTS STATEMENT**

447 BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Pfizer, Roche, and  
448 Sanofi Pasteur. The authors report no other potential conflicts of interest.

449 **REFERENCES**

- 450 1. World Health Organization. WHO COVID-19 Dashboard. 2020.  
451 <https://covid19.who.int/> (accessed 24 October 2022).
- 452 2. Fineberg HV. Pandemic preparedness and response--lessons from the H1N1  
453 influenza of 2009. *N Engl J Med* 2014; **370**(14): 1335-42.
- 454 3. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2  
455 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg Infect Dis* 2022; **28**(9):  
456 2022.04.07.22273595.
- 457 4. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the  
458 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet* 2022;  
459 **399**(10323): 437-46.
- 460 5. Sachs JD, Karim SSA, Akinin L, et al. The Lancet Commission on lessons for the  
461 future from the COVID-19 pandemic. *Lancet* 2022; **400**(10359): 1224-80.
- 462 6. Sonabend R, Whittles LK, Imai N, et al. Non-pharmaceutical interventions,  
463 vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling  
464 study. *Lancet* 2021; **398**(10313): 1825-35.
- 465 7. De Foo C, Grépin KA, Cook AR, et al. Navigating from SARS-CoV-2 elimination to  
466 endemicity in Australia, Hong Kong, New Zealand, and Singapore. *Lancet* 2021;  
467 **398**(10311): 1547-51.
- 468 8. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and  
469 three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-  
470 based observational study. *Lancet Infect Dis* 2022.
- 471 9. Adam DC, Wu P, Wong JY, et al. Clustering and superspreading potential of SARS-  
472 CoV-2 infections in Hong Kong. *Nat Med* 2020; **26**(11): 1714-9.

- 473 10. Young BR, Yang B, Wu P, et al. Residential clustering of COVID-19 cases and  
474 efficiency of building-wide compulsory testing notices as a transmission control  
475 measure in Hong Kong. *J Infect Dis* 2023.
- 476 11. Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in factors  
477 associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong:  
478 Serial cross-sectional surveys. *The Lancet Regional Health – Western Pacific* 2022; **23**.
- 479 12. Yang B, Tsang TK, Gao H, et al. Universal Community Nucleic Acid Testing for  
480 Coronavirus Disease 2019 (COVID-19) in Hong Kong Reveals Insights Into Transmission  
481 Dynamics: A Cross-Sectional and Modeling Study. *Clin Infect Dis* 2022; **75**(1): e216-e23.
- 482 13. Leung K, Wu JT, Leung GM. Real-time tracking and prediction of COVID-19  
483 infection using digital proxies of population mobility and mixing. *Nature*  
484 *Communications* 2021; **12**(1): 1501.
- 485 14. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to  
486 estimate time-varying reproduction numbers during epidemics. *Am J Epidemiol* 2013;  
487 **178**(9): 1505-12.
- 488 15. Fraser C. Estimating individual and household reproduction numbers in an  
489 emerging epidemic. *PLoS One* 2007; **2**(8): e758.
- 490 16. Becker DJ, Linebarger DA. Constrained iterative deconvolution applied to  
491 bearing and amplitude estimation of coherent sources. [1991] Conference Record of the  
492 Twenty-Fifth Asilomar Conference on Signals, Systems & Computers; 1991 4-6 Nov.  
493 1991; 1991. p. 579-82 vol.1.
- 494 17. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel  
495 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; **382**(13): 1199-207.

- 496 18. Manica M, De Bellis A, Guzzetta G, et al. Intrinsic generation time of the SARS-  
497 CoV-2 Omicron variant: An observational study of household transmission. *Lancet Reg*  
498 *Health Eur* 2022; **19**: 100446.
- 499 19. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and  
500 transmissibility of COVID-19. *Nat Med* 2020; **26**(5): 672-5.
- 501 20. Pei S, Yamana TK, Kandula S, Galanti M, Shaman J. Burden and characteristics of  
502 COVID-19 in the United States during 2020. *Nature* 2021; **598**(7880): 338-41.
- 503 21. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19  
504 outbreaks by isolation of cases and contacts. *Lancet Glob Health* 2020; **8**(4): e488-e96.
- 505 22. Li Y, Campbell H, Kulkarni D, et al. The temporal association of introducing and  
506 lifting non-pharmaceutical interventions with the time-varying reproduction number (R)  
507 of SARS-CoV-2: a modelling study across 131 countries. *Lancet Infect Dis* 2021; **21**(2):  
508 193-202.
- 509 23. Xiao J, Cowling BJ, Leung GM. Transitioning from covid-19 elimination to  
510 sustainable endemicity in East Asia. 2021.  
511 [https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-](https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-sustainable-endemicity-in-east-asia/)  
512 [sustainable-endemicity-in-east-asia/](https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-sustainable-endemicity-in-east-asia/) (accessed 6 May 2023 2023).
- 513 24. Yang B, Tsang TK, Wong JY, et al. The differential importation risks of COVID-19  
514 from inbound travellers and the feasibility of targeted travel controls: A case study in  
515 Hong Kong. *Lancet Reg Health West Pac* 2021; **13**: 100184.
- 516 25. Yang B, Sullivan SG, Du Z, Tsang TK, Cowling BJ. Effectiveness of International  
517 Travel Controls for Delaying Local Outbreaks of COVID-19. *Emerg Infect Dis* 2022; **28**(1):  
518 251-3.
- 519 26. Gu H, Xie R, Adam DC, et al. Genomic epidemiology of SARS-CoV-2 under an  
520 elimination strategy in Hong Kong. *Nature Communications* 2022; **13**(1): 736.

- 521 27. Du Z, Wang L, Shan S, et al. Pandemic fatigue impedes mitigation of COVID-19 in  
522 Hong Kong. *Proceedings of the National Academy of Sciences* 2022; **119**(48):  
523 e2213313119.
- 524 28. The Economist. Why Hong Kong's 'Zero-covid' strategy could backfire? 2021.  
525 [https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-](https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-zero-covid-strategy-could-backfire)  
526 [zero-covid-strategy-could-backfire](https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-zero-covid-strategy-could-backfire) (accessed 26 May 2023 2023).
- 527 29. Yuan J, Lam WTW, Xiao J, Ni YM, Cowling BJ, Liao Q. Why do Chinese older adults  
528 in Hong Kong delay or refuse COVID-19 vaccination? A qualitative study based on  
529 Grounded Theory. *The Journals of Gerontology: Series B* 2022: gbac184.
- 530 30. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the  
531 Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
- 532 31. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-  
533 CoV-2 Omicron and Delta variants. *Nat Med* 2022; **28**(5): 1063-71.
- 534 32. Boon SS, Wong MCS, Ng RWY, et al. Seroprevalence of Unidentified SARS-CoV-2  
535 Infection in Hong Kong During 3 Pandemic Waves. *JAMA Netw Open* 2021; **4**(11):  
536 e2132923.
- 537 33. Poon RW, Chan BP, Chan WM, et al. SARS-CoV-2 IgG seropositivity after the  
538 severe Omicron wave of COVID-19 in Hong Kong. *Emerg Microbes Infect* 2022; **11**(1):  
539 2116-9.
- 540 34. To KK, Cheng VC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in  
541 residents evacuated from Hubei province, China: a multicohort study. *Lancet Microbe*  
542 2020; **1**(3): e111-e8.
- 543 35. Wong JY, Cheung JK, Lin Y, et al. Intrinsic and effective severity of COVID-19  
544 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong.  
545 *medRxiv* 2023: 2023.02.13.23285848.

546 **FIGURE LEGENDS**

547 **Figure 1.** Confirmed cases (A), transmission dynamics (B), non-pharmaceutical  
548 interventions (NPIs, C), testing schemes (D), self-reported population behaviours (E),  
549 and population mobility (F) across the six epidemic waves of COVID-19 in Hong Kong.  
550 (A) COVID-19 cases. Coloured bars indicated cases laboratory-confirmed by RT-PCR or  
551 self-reported rapid antigen test (RAT) positives, which were only available after  
552 February 25, 2022. Laboratory-cases were classified into sporadic/index imported  
553 (dark blue), linked-to-imported (light blue), sporadic/index local (brown) and contacts  
554 of local COVID-19 cases (orange). Self-reported RAT positive cases were classified into  
555 imported (green) or local (pink) cases. Pie charts shows the share of case type for the  
556 first four waves. (B) Estimated effective reproduction numbers ( $R_t$ ) for local  
557 transmission based on identified local cases. Shaded areas in dark grey indicated the  
558 estimated 95% credible intervals of  $R_t$ . (C) NPIs taken to suppress and contain the  
559 Covid-19 transmission in Hong Kong by time. NPIs were classified into three target  
560 groups: inbound travellers (blue), community (yellow) and case and contact tracing  
561 (red). Darker shading represents more stringent measures, with details in Table S4. (D)  
562 COVID-19 testing schemes by target groups and settings. Items with asterisks indicate  
563 testing for individuals with respiratory illness. (E) Population behaviours related to  
564 physical distancing and personal hygiene measured among the general adult population  
565 across 107 cross-sectional telephone surveys, January 2020 to December 2022. Point  
566 estimates (points) and 95% confidence intervals (vertical segments) were estimated by  
567 each survey. (F) Percentage changes in transport transactions using Octopus cards  
568 relative to 1 January 2020, weighted by age-structure of Hong Kong population in 2021.  
569



570 **Figure 2.** Prediction of effective reproduction numbers ( $R_t$ ) of COVID-19 associated  
571 with non-pharmaceutical interventions (NPIs) taken across epidemic waves. Wave-  
572 specific intercepts were used as the baseline level for each epidemic wave. **(A)** NPIs  
573 packages used for model prediction: the most stringent measures used in each epidemic  
574 wave, no measure, and all measures. **(B)** Wave-specific  $R_t$  (row) when no or all  
575 measures (column) were implemented. **(C)** Wave-specific  $R_t$  (row) under the most  
576 stringent NPIs packages (column) of each epidemic wave.

577

578 **Figure 3.** Confirmed deaths, vaccine coverage, and antiviral usages across the six  
579 epidemic waves of COVID-19 in Hong Kong. **(A)** Confirmed COVID-19 deaths sorted by  
580 date of confirmation. Coloured bars indicated whether the fatal cases were aged 65  
581 years or above (red) or otherwise (blue). **(B)** Cumulative coverage of one, two, three or  
582 four doses of CoronaVac and/or BNT162b2. **(C)** Antiviral usage among confirmed  
583 COVID-19 cases aged 65 and above sorted by date of confirmation.

584

585 **Figure 4.** Disease severity and burden of COVID-19 and implementations of  
586 pharmaceutical interventions taken across epidemic waves. Estimates were stratified  
587 by wave and trajectory. We also calculated the estimates for all Hong Kong population  
588 (overall), individuals aged 65y and above, and unvaccinated individuals of all ages  
589 (unvaccinated). **(A)** Mortality rate per 1000 persons per week. **(B)** Case-fatality risk.  
590 Cases were all notified cases, including PCR and RAT positives. **(C)** Coverage of  
591 individuals received two or more doses of COVID-19 vaccines. Vaccine coverage among  
592 both all Hong Kong (overall; light colours) and individuals aged  $\geq 65y$  (dark colours)  
593 were calculated. **(D)** Antiviral usage among confirmed COVID-19 cases aged 65 and  
594 above. **(E)** Case-fatality risk and antiviral usage in the fifth and sixth wave. Estimates

595 were calculated for unvaccinated individuals aged  $\geq 65$ y. **(F)** Case-fatality risk and  
596 COVID-19 vaccine coverage in the fifth and sixth wave. We calculated vaccine coverage  
597 as individuals aged 65 and above and received two or more doses. Case-fatality risk was  
598 calculated for all adults  $\geq 65$ y and fully vaccinated adults  $\geq 65$ y, respectively. **(G)**  
599 Mortality rate and COVID-19 vaccine coverage in the fifth and sixth wave. We calculated  
600 vaccine coverage as individuals aged  $\geq 65$ y who had received two or more doses.  
601 Mortality rate was calculated for all adults  $\geq 65$ y and fully vaccinated adults  $\geq 65$ y,  
602 respectively.

**Table 1. Characteristics of COVID-19 cases confirmed in Hong Kong by epidemic wave.**

	Wave 1&2	Wave 3	Wave 4	Post wave 4	Wave 5a	Wave 5b		Wave 6a		Wave 6b		p <sup>1</sup>
	(1/1/20-30/4/20)	(1/5/20-30/9/20)	(1/10/20-30/4/21)	(1/5/21-30/12/21)	(31/12/21-6/2/22)	PCR	RAT	PCR	RAT	PCR	RAT	
<b>N</b>	1038	4050	6682	861	2804	745787	449173	189298	365711	222148	638080	
<b>Age group (n, %)</b>												<0.001
0-18	108 (10.4)	374 (9.2)	591 (8.8)	87 (10.1)	437 (15.6)	62994 (8.4)	55915 (12.4)	18932 (10.0)	65650 (18.0)	14726 (6.6)	107658 (16.9)	
19-29	308 (29.7)	611 (15.1)	931 (13.9)	219 (25.4)	464 (16.5)	85369 (11.4)	61363 (13.7)	21395 (11.3)	48326 (13.2)	24416 (11.0)	76807 (12.0)	
30-44	272 (26.2)	936 (23.1)	1917 (28.7)	315 (36.6)	767 (27.4)	169209 (22.7)	126669 (28.2)	40886 (21.6)	101816 (27.8)	52147 (23.5)	171390 (26.9)	
45-64	269 (25.9)	1376 (34.0)	2132 (31.9)	203 (23.6)	836 (29.8)	263295 (35.3)	131810 (29.3)	63887 (33.7)	105726 (28.9)	78735 (35.4)	194644 (30.5)	
≥65	81 (7.8)	753 (18.6)	1111 (16.6)	37 (4.3)	296 (10.6)	157587 (21.1)	73035 (16.3)	43719 (23.1)	43959 (12.0)	51794 (23.3)	87069 (13.6)	
Missing	--	--	--	--	4 (0.1)	7333 (1.0)	381 (0.1)	479 (0.3)	234 (0.1)	330 (0.1)	512 (0.1)	
<b>Sex (n, %)</b>												<0.001
Male	559 (53.9)	1960 (48.4)	3134 (46.9)	452 (52.5)	1316 (46.9)	366375 (49.1)	193498 (43.1)	91853 (48.5)	164372 (44.9)	105579 (47.5)	278859 (43.7)	
Female	479 (46.1)	2090 (51.6)	3548 (53.1)	409 (47.5)	1484 (52.9)	372618 (50.0)	255512 (56.9)	97021 (51.3)	201173 (55.0)	116310 (52.4)	358752 (56.2)	
Missing	--	--	--	--	4 (0.1)	6794 (0.9)	163 (0.0)	424 (0.2)	166 (0.0)	259 (0.1)	469 (0.1)	
<b>Case classifications (n, %)</b>												
Sporadic/index imported	616 (59.3)	664 (16.4)	1107 (16.6)	841 (97.7)	610 (21.8)	1156 (0.2)	221 (0.05)	18886 (10.0)	2985 (0.8)	45286 (20.4)	6628 (1.0)	
Linked-to-imported	88 (8.5)	5 (0.1)	11 (0.2)	10 (1.2)	848 (30.2)	56 (0.01)	4 (0.001)	7 (0.0)	30 (0.01)	0 (0.0)	0 (0.0)	

Local	169 (16.3)	1293 (31.9)	1795 (26.9)	5 (0.6)	485 (17.3)	740658 (99.3)	448822 (99.9)	170186 (89.9)	362227 (99.0)	176862 (79.6)	631452 (99.0)	
Contact of local	165 (15.9)	2088 (51.6)	3769 (56.4)	5 (0.6)	861 (30.7)	3917 (0.5)	126 (0.03)	219 (0.04)	469 (0.1)	0 (0.0)	0 (0.0)	
<b>Severity status (n, %)</b>												<0.001
Severe	57 (5.5)	495 (12.2)	924 (13.8)	27 (3.1)	69 (2.5)	11978 (1.6)	1511 (0.3)	3635 (1.9)	1199 (0.3)	5753 (2.6)	2275 (0.4)	
Critical	50 (4.8)	144 (3.6)	211 (3.2)	3 (0.3)	3 (0.1)	1508 (0.2)	143 (0.0)	435 (0.2)	110 (0.0)	643 (0.3)	248 (0.0)	
Fatal	5 (0.5)	105 (2.6)	102 (1.5)	1 (0.1)	3 (0.1)	8969 (1.2)	704 (0.2)	682 (0.4)	174 (0.0)	1661 (0.7)	728 (0.1)	
<b>Delay distribution, days (mean, sd)</b>												
Onset to hospitalization <sup>2</sup>	5.8 (5.4)	4.7 (4.2)	3.2 (3.0)	2.5 (4.6)	2.6 (2.3)	5.0 (7.3)	11.6(10.4)	4.5 (11.4)	6.7 (16.3)	3.7 (10.1)	8.0 (12.3)	<0.001
Onset to confirmation	6.5 (5.4)	5.2 (3.8)	4.3 (3.0)	3.7 (4.4)	2.8 (1.7)	5.5 (5.4)	2.3 (4.9)	4.6 (41.0)	4.2 (5.5)	2.7 (12.9)	4.2 (35.2)	<0.001
Onset to discharge	29.1 (13.2)	18.6 (14.2)	17.3 (15.2)	20.9 (9.9)	14.4 (4.6)	17.5(20.3)	21.5 (17.1)	11.3 (14.2)	13.0 (18.5)	10.1 (11.6)	13.1 (13.5)	<0.001
Onset to death	36.4 (54.2)	36 (79.3)	29.9 (28.6)	--	31.0 (--) <sup>3</sup>	11.9 (9.1)	17.7 (11.4)	14.2 (7.6)	14.4 (8.7)	16.1 (29.5)	15.5 (8.6)	<0.001
Confirmation to last positive sample	18.0 (12.5)	10.7 (25.7)	9.5 (10.2)	10.4 (6.8)	8.9 (4.6)	8.0 (19.1)	5.8 (16.6)	6.9 (9.0)	6.1 (8.3)	6.5 (6.5)	6.1 (5.9)	<0.001

<sup>1</sup> Fisher's exact test was used for categorical variables and Kruskal-Wallis rank sum test was used for all continuous variables.



<sup>2</sup> 5,215 (10%) cases were excluded from the analysis due to the recorded date of onset later than the date of hospital admission (possibly nosocomial infection)

<sup>3</sup> Only one case died eventually among all COVID-19 cases confirmed during Wave 5a



**A**Strength level  None  Moderate  Strict

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.20.23291593>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**B****C**